PDL BioPharma (PDLI) Reports 4Q Earnings: It’s a Miss

PDL BioPharma, Inc. (PDLI) reported fourth quarter non-GAAP EPS of $0.32 after the close Monday, compared to the consensus estimate of $0.57. Revenues increased 4.5% from last year to $117.1 million. Analysts expected revenues of $158.15 million. The stock is now down $0.46 to $6.88 on 3.5 million shares. For full year 2014, total revenues […] View the full post at: PDL BioPharma (PDLI) Reports 4Q Earnings: It’s a Miss Related posts: Encouraging Reports but Meaningful Growth is Still a Ways Off JPMorgan Posts Better-than-Expected Results Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock